David B. Page, MD
There are hundreds of targets and therapies in development for the treatment of patients with triple-negative breast cancer (TNBC), according to David B. Page, MD, a medical oncologist at Earle A. Chiles Research Institute of Providence Cancer Center.
State of the Science Summit™ on Breast Cancer, Page discussed emerging treatment approaches for patients with TNBC.
OncLive: How has the treatment landscape evolved in TNBC?
: There are so many new directions in the treatment of patients with metastatic TNBC. Immunotherapy is probably one of the most exciting directions. Immunotherapy is not 1 drug, but rather a broad class of medications. We are just seeing the tip of the iceberg. We're starting to see that PD-1 antibodies can reinvigorate immune responses against cancer. I presented some data that show response rates of approximately 10% to 26%.
There are some promising chemotherapy modifications with pegylation that have been evaluated. Another strategy is combining chemotherapy with targeted therapy by conjugating antibodies to strong chemotherapies. This subsequently directs the chemotherapy to where it matters. That way, we can target the cancer and spare normal cells.
Will we continue to use the term TNBC as more specific subtypes are identified?
As long as we have effective therapies for patients who don’t have TNBC, the designation for [TNBC] is going to be imperative. For patients with hormone-sensitive [breast cancer], we are going to use hormone blockers. I don't think that is going to disappear anytime soon.
[The landscape] is going to become much more complex; there will be multiple parameters that are not only looking at genes or specific protein expression, but potentially the immune dynamics of tumors. There might be some breast cancers that are labeled as triple negative, which have enriched immune signatures or certain types of immune cells that can be targeted differently.
It will become much more complicated, but in a good way. Eventually, the number of parameters will require us to use computers to sort through these data. That is my prediction. We will have to harmonize medicine with statistics and informatics in order to treat patients appropriately.
How has olaparib helped patients with BRCA-positive breast cancers?
We have seen responses greater than 50%; we’ve seen responses that are somewhat durable, relative to some chemotherapies. We're trying to expand on that 10% benefit in understanding that BRCA
is not the only relevant gene. There may be other genes that could confer sensitivity to olaparib (Lynparza). There are ways of categorizing a tumor based on its defects in repairing DNA.
... to read the full story